{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:13:31Z","timestamp":1781842411946,"version":"3.54.5"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.biopha.2025.117973","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T03:48:44Z","timestamp":1743565724000},"page":"117973","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Single cell multi-omics reveals re-dosing with CD3 bispecific antibody induces a TCF7 high central memory CD8\u202f+\u202fT cell population associated with reduced cytokine production"],"prefix":"10.1016","volume":"186","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1635-1948","authenticated-orcid":false,"given":"Hui","family":"Ling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2511-1159","authenticated-orcid":false,"given":"Lauren","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Kubek-Luck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Perner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Burks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Schuierer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera M.","family":"Ruda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5891","key":"10.1016\/j.biopha.2025.117973_bib1","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"issue":"18","key":"10.1016\/j.biopha.2025.117973_bib2","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.117973_bib3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2025.117973_bib4","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.biopha.2025.117973_bib5","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.biopha.2025.117973_bib6","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s41416-020-01225-5","article-title":"Overcoming the challenges associated with CD3+\u2009T-cell redirection in cancer","volume":"124","author":"Singh","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2025.117973_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000621","article-title":"Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies","volume":"8","author":"Kauer","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.biopha.2025.117973_bib8","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"508","key":"10.1016\/j.biopha.2025.117973_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax8861","article-title":"CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity","volume":"11","author":"Li","year":"2019","journal-title":"Sci. Transl. Med"},{"issue":"1","key":"10.1016\/j.biopha.2025.117973_bib10","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1038\/s41467-023-38723-y","article-title":"Neutralizing IFNgamma improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies","volume":"14","author":"Manni","year":"2023","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2025.117973_bib11","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1158\/2643-3230.BCD-21-0181","article-title":"Blockade or deletion of IFNgamma reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies","volume":"3","author":"Bailey","year":"2022","journal-title":"Blood Cancer Discov."},{"issue":"13","key":"10.1016\/j.biopha.2025.117973_bib12","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.biopha.2025.117973_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110266","article-title":"CXCR3 regulates stem and proliferative CD8+\u2009T cells during chronic infection by promoting interactions with DCs in splenic bridging channels","volume":"38","author":"Bangs","year":"2022","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.biopha.2025.117973_bib14","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1038\/s41467-019-12464-3","article-title":"Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease","volume":"10","author":"Szabo","year":"2019","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.biopha.2025.117973_bib15","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.ccell.2023.08.013","article-title":"ZNF683 marks a CD8(+) T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome","volume":"41","author":"Parry","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.biopha.2025.117973_bib16","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1038\/s41467-020-15543-y","article-title":"Single-cell transcriptomics identifies an effectorness gradient shaping the response of CD4(+) T cells to cytokines","volume":"11","author":"Cano-Gamez","year":"2020","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.biopha.2025.117973_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002582","article-title":"Src\/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies","volume":"9","author":"Leclercq","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.biopha.2025.117973_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005956","article-title":"Dasatinib for treatment of CAR T-cell therapy-related complications","volume":"10","author":"Baur","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2025.117973_bib19","first-page":"163","article-title":"Teclistamab-cqyv: the first bispecific T-cell engager antibody for the treatment of patients with relapsed or refractory multiple myeloma","volume":"14","author":"Hua","year":"2023","journal-title":"J. Adv. Pr. Oncol."},{"key":"10.1016\/j.biopha.2025.117973_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2022.115986","article-title":"Priming treatment with T-cell redirecting bispecific antibody ERY974 reduced cytokine induction without losing cytotoxic activity in vitro by changing the chromatin state in T cells","volume":"441","author":"Iwata","year":"2022","journal-title":"Toxicol. Appl. Pharm."},{"issue":"5","key":"10.1016\/j.biopha.2025.117973_bib21","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.immuni.2020.09.005","article-title":"Central memory CD8(+) T cells derive from stem-like Tcf7(hi) effector cells in the absence of cytotoxic differentiation","volume":"53","author":"Pais Ferreira","year":"2020","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.biopha.2025.117973_bib22","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining 'T cell exhaustion","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2025.117973_bib23","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.immuni.2019.09.013","article-title":"TCF-1-centered transcriptional network drives an effector versus exhausted CD8 T cell-fate decision","volume":"51","author":"Chen","year":"2019","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.biopha.2025.117973_bib24","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41590-022-01131-3","article-title":"Tcf1 preprograms the mobilization of glycolysis in central memory CD8(+) T cells during recall responses","volume":"23","author":"Shan","year":"2022","journal-title":"Nat. Immunol."},{"issue":"510","key":"10.1016\/j.biopha.2025.117973_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aan4931","article-title":"IL-2Rbeta abundance differentially tunes IL-2 signaling dynamics in CD4(+) and CD8(+) T cells","volume":"10","author":"Smith","year":"2017","journal-title":"Sci. Signal"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225001672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225001672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T22:56:06Z","timestamp":1781823366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225001672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":25,"alternative-id":["S0753332225001672"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.117973","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single cell multi-omics reveals re-dosing with CD3 bispecific antibody induces a TCF7 high central memory CD8\u202f+\u202fT cell population associated with reduced cytokine production","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.117973","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117973"}}